• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小细胞肺癌患者静脉血栓栓塞的风险因素。

Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.

机构信息

Oncology Unit, 3 Department of Medicine, "Sotiria" General Hospital, Schoolof Medicine, National and Kapodistrian University of Athens, Athens, Greece

Oncology Unit, 3 Department of Medicine, "Sotiria" General Hospital, Schoolof Medicine, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Anticancer Res. 2021 Mar;41(3):1523-1528. doi: 10.21873/anticanres.14911.

DOI:10.21873/anticanres.14911
PMID:33788745
Abstract

BACKGROUND/AIM: Small cell lung cancer (SCLC) accounts for 13% of all lung cancers. Venous thromboembolism (VTE) is a frequent complication. The purpose of this study was to investigate the incidence and risk factors for VTE in SCLC patients.

PATIENTS AND METHODS

Retrospective analysis of patients with histologically confirmed SCLC treated between January 2015 and June 2018 at Sotiria General Hospital, Athens, Greece.

RESULTS

Two hundred and seventeen patients were included in the analysis. The incidence of VTE was 4.1%. Increased body mass index (BMI) was correlated with the development of VTE. Moreover, VTE appeared more frequently in patients with major vessel infiltration and with poor Eastern Cooperative Oncology Group Performance Status. Other factors, including gender, age, stage, presence of metastasis, treatment, immobilization, anticoagulation, comorbidities, and laboratory values did not correlate with the development of VTE.

CONCLUSION

Factors associated with the development of VTE were BMI, major vessel infiltration and PS. Identifying factors that predispose to VTE could help physicians detect high-risk patients who would benefit from prophylactic anticoagulation therapy.

摘要

背景/目的:小细胞肺癌(SCLC)约占所有肺癌的 13%。静脉血栓栓塞症(VTE)是一种常见的并发症。本研究旨在探讨 SCLC 患者 VTE 的发生率和危险因素。

患者和方法

回顾性分析了 2015 年 1 月至 2018 年 6 月在希腊雅典 Sotiria 综合医院接受治疗的经组织学证实的 SCLC 患者。

结果

共纳入 217 例患者进行分析。VTE 的发生率为 4.1%。体重指数(BMI)增加与 VTE 的发生相关。此外,大血管浸润和东部合作肿瘤学组(ECOG)表现状态差的患者 VTE 更常见。其他因素,包括性别、年龄、分期、转移、治疗、固定、抗凝、合并症和实验室值与 VTE 的发生无关。

结论

与 VTE 发生相关的因素是 BMI、大血管浸润和 PS。确定易发生 VTE 的因素有助于医生发现高危患者,这些患者可能受益于预防性抗凝治疗。

相似文献

1
Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.小细胞肺癌患者静脉血栓栓塞的风险因素。
Anticancer Res. 2021 Mar;41(3):1523-1528. doi: 10.21873/anticanres.14911.
2
A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.利伐沙班和达肝素用于长期治疗肺癌合并静脉血栓栓塞症患者的疗效和安全性的回顾性研究。
Respiration. 2019;98(3):203-211. doi: 10.1159/000499895. Epub 2019 May 16.
3
The incidence of venous thromboembolism among patients with primary lung cancer.原发性肺癌患者静脉血栓栓塞的发生率。
J Thromb Haemost. 2008 Apr;6(4):601-8. doi: 10.1111/j.1538-7836.2008.02908.x. Epub 2008 Jan 17.
4
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).肺癌静脉血栓栓塞症和早期死亡率的预测因素:一项全球前瞻性研究(CANTARISK)的结果。
Oncologist. 2018 Feb;23(2):247-255. doi: 10.1634/theoncologist.2017-0205. Epub 2017 Sep 26.
5
Venous thromboembolism in non-small cell lung cancer patients who underwent surgery after induction therapy.接受诱导治疗后接受手术的非小细胞肺癌患者的静脉血栓栓塞
Gen Thorac Cardiovasc Surg. 2020 Oct;68(10):1156-1162. doi: 10.1007/s11748-020-01351-0. Epub 2020 Apr 9.
6
Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients.中国非小细胞肺癌患者的静脉血栓栓塞危险因素
Support Care Cancer. 2015 Mar;23(3):635-41. doi: 10.1007/s00520-014-2405-y. Epub 2014 Aug 27.
7
Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer.中性粒细胞-淋巴细胞比值在肺癌合并静脉血栓栓塞症患者中的临床意义。
Lung Cancer. 2014 Apr;84(1):79-85. doi: 10.1016/j.lungcan.2014.01.014. Epub 2014 Jan 28.
8
Venous thromboembolism in patients with severe lung cancer: a narrative review.重度肺癌患者的静脉血栓栓塞:一项叙述性综述
Ann Palliat Med. 2021 Jun;10(6):6957-6967. doi: 10.21037/apm-21-1281. Epub 2021 Jun 7.
9
Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.识别静脉血栓栓塞的风险因素,并评估 Khorana 静脉血栓栓塞风险评估在日本肺癌患者中的应用。
J Cardiol. 2020 Jan;75(1):110-114. doi: 10.1016/j.jjcc.2019.06.013. Epub 2019 Aug 12.
10
[Risk Factors Associated with Venous Thromboembolism after Lung Cancer Surgery: A Single-center Study].[肺癌手术后静脉血栓栓塞的相关危险因素:一项单中心研究]
Zhongguo Fei Ai Za Zhi. 2018 Oct 20;21(10):753-760. doi: 10.3779/j.issn.1009-3419.2018.10.04.

引用本文的文献

1
Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.肺癌患者静脉血栓栓塞症的患病率及临床特征:一项系统评价和荟萃分析。
Front Oncol. 2024 Aug 14;14:1405147. doi: 10.3389/fonc.2024.1405147. eCollection 2024.
2
Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review.肺癌患者静脉血栓栓塞症的管理:最新综述。
BMJ Open Respir Res. 2023 Apr;10(1). doi: 10.1136/bmjresp-2022-001493.